In a report released today, Michael Petusky from Barrington maintained a Buy rating on Opko Health (OPK), with a price target of $7. The company’s shares opened today at $3.37.
Petusky observed:
“We are maintaining our OUTPERFORM investment rating on OPK shares and our price target remains $7. We arrive at our price target via a DCF methodology for its current commercial business plus the hGH-CTP program. We assign an additional $1 of value for the rest of OPKO’s product pipeline.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 12.5% and a 59.1% success rate. Petusky covers the Services sector, focusing on stocks such as US Physical Therapy, Tivity Health Inc, and BioScrip Inc.
Currently, the analyst consensus on Opko Health is a Moderate Buy with an average price target of $13.50, implying a 300.6% upside from current levels. In a report issued on November 9, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $20 price target.
.
See today’s analyst top recommended stocks >>
Based on Opko Health’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.2 million. In comparison, last year the company had a GAAP net loss of $46.44 million.
Based on the recent corporate insider activity of 95 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations.
Read More on OPK:
